Other Events ·
Ocugen adjourns vote to increase authorized common stock by 250M shares until October 26
OCGNOcugen, Inc.
Ocugen reconvened its Special Meeting of Stockholders on October 5, 2026, but adjourned the meeting solely regarding Proposal 1. The proposal seeks to amend the Company’s Sixth Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock by 250,000,000 shares. The Adjourned Meeting is scheduled for October 26, 2026, at 8:00 a.m. Eastern Time. The record date remains July 27, 2026. Ocugen operates in the biotechnology industry, focusing on gene therapy and vaccine development.